- Cell Therapeutics (CTIC) has received market access from France's National Health Authority for the company's Pixuvri drug to treat patients with advanced B-cell non-Hodgkin lymphoma.
- Pixuvri now needs to be approved for hospital use so that patients can receive reimbursement for the drug.
- Shares fly 17.9%. (PR)
Cell Therapeutics gets French approval for non-Hodgkin lymphoma drug
Aug 19 2013, 07:35 ET